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ABSTRACT 16 
Women with polycystic ovary syndrome (PCOS) in their r productive years age present with metabolic 17 
dysfunction and thus increased likelihood of long-term health consequences and diminished well-being in 18 
later life. Due to their larger ovarian reserve, however, they may experience menopause at later age and 19 
protection from metabolic and cardiovascular diseases. Moreover, previous studies have indicated that late 20 
reproductive aged, normal-weight women with PCOS do not seem to have the expected high risk for type 2 21 
diabetes (T2D), as previously thought. Health related quality of life (HRQoL), nevertheless, is decreased in 22 
women with PCOS up until late fertile age, warranting attention and actions from the health care personnel. 23 
Given conflicting reports regarding the risk of cardiovascular diseases, future research with well 24 
characterized and adequately sized PCOS populations are needed as well as studies aiming to improve their25 
HRQoL. 26 
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INTRODUCTION 28 
 29 
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy among women in their 30 
reproductive years with life-long adverse health impact reflected by decreased health related quality of 31 
life (HRQoL) (1, 2). PCOS is characterized by the presence of hyperandrogenism, oligo- or 32 
anovulation, and polycystic ovary morphology, and the syndrome associates with high risk of obesity 33 
and metabolic derangements (3). Prior studies have reported that severity of PCOS phenotype 34 
diminishes with age (4), with aging-related decreases in ovarian and adrenal androgen levels (5-8), 35 
ovarian volume and follicle numbers, accompanying icreasingly regular menstrual cycles (9-11). 36 
Testosterone levels, however, remain higher than in non-PCOS women (5-8). 37 
 38 
Given that women with PCOS have higher anti-Müllerian hormone (AMH) levels and ovarian antral 39 
follicle count (9, 12), it has also been speculated  that they might have a longer reproductive life span 40 
and later menopause (13). As the number of ovarian antral follicles decline, menstrual cycles become 41 
more regular, and androgen levels decrease over time, t has led to an idea that the metabolic 42 
derangements might also resolve. Long-term studies in women with PCOS reaching beyond menopause 43 
are, however, scarce and the hormonal and metabolic changes during the late reproductive years and 44 
beyond menopause are poorly understood. This mini review aims to provide a brief insight into the 45 
literature regarding the effects of ageing and menopause on reproductive and metabolic features, and 46 
long-term HRQoL outcomes, in women with PCOS.   47 
MAIN TEXT OF REVIEW 48 
Reproductive life span and age at menopause 49 
Women with PCOS have higher number of ovarian antral follicles and possibly greater ovarian reserve than 50 
non-PCOS women (14). A previous study reported thatwomen with PCOS may gain regular menstrual 51 
cycles with aging (11), however, only a few studies have investigated ovarian aging or age at menopause in 52 
the affected women. A longitudinal study of 31 women with PCOS and 266 controls, recruited from a 53 
tertiary academic centre, reported women with PCOS and control women having a similar decline rate of 54 
antral follicles, after adjusting for baseline antrl follicle count and age (15). In our previous study assessing 55 
109 women (44 controls and 65 women with PCOS), the decline in AMH levels was comparable in both 56 
study groups, although AMH levels were always 2- to 3-f ld higher and remained elevated until 40 years of 57 
age in in women with PCOS (9). As for menopausal age,  cohort study with a 24-year follow up found that 58 
women with PCOS diagnosed by having oligomenorrhea and hyperandrogenism (n=27) reached menopause 59 
four years later than control women (n=94) (16). In line with this result, another Swedish study found that 60 
PCOS was associated with a later age at menopause (Hazard ratio: 0.44 [0.28 – 0.71]) (13). Similarly, the 61 
Tehran Lipid and Glucose Cohort study using a prediction model based on AMH levels, estimated the age at 62 
menopause to be 51.4 years in women with PCOS and 49.7 years in the controls (17). Interestingly, women 63 
with PCOS  have also been suggested to have earlier menopause than their non-PCOS counterparts (18).  64 
Taking together, only a few studies have investigated the age at menopause in women with PCOS, but the 65 
available evidence indicates that women with PCOS enter menopause later than their non-PCOS 66 
counterparts. In agreement with this, a previous GWAS study demonstrated that genetic variants associated 67 
with menopausal age have a robust association with variants associated with PCOS (19). Whether all this68 
translates into fertility in the late reproductive y ars for women with PCOS and consequently longer estrogen 69 
exposure, remains to be determined. As the alleles r ated to later menopause have also been associated with 70 
more effective DNA repair, women with PCOS may not experience increased cardiovascular events as 71 
predicted from their metabolic profile during their earlier reproductive years. A recent study, however, 72 
reported shorter telomere length in women with PCOS and infertility compared to controls, and thus didnot 73 
support longer life expectancy in this population (20). Whether diminished telomere length applies to all 74 
women with PCOS and not just those suffering from infertility remains to be investigated. This question 75 
warrants larger future studies that employ a longitudinal design of the same individuals. 76 
Excess weight 77 
Women with PCOS are commonly overweight or obese (21), with the rate of obesity depending on ethnicity 78 
and cultural background (22). Recent studies have identified a causal link between PCOS and BMI-related 79 
genes (19, 23), although the susceptibility to obesity in affected women is complex, with environmental 80 
factors also playing a role. Increased body weight occurs early in girls who ultimately manifest PCOS 81 
phenotypes as shown in our previous population based birth cohort (The Northern Finland Birth Cohort, 82 
NFBC66) data assessing BMI trajectories from birth until 18 years in women with and without PCOS (24). 83 
Interestingly, the rise in BMI around the age of 5 years in children, termed adiposity rebound (AR), occurs 84 
almost 5 months earlier on average in girls later diagnosed with PCOS. Given that the early timing of AR 85 
was also associated with a PCOS diagnosis independently of BMI (24), precocious AR could be a sign of 86 
increased PCOS risk. Recently published longitudinal studies have also indicated that rapid weight gain 87 
during adolescence or the early reproductive years is common in PCOS (25, 26). Furthermore, the NFBC66 88 
study with an ongoing follow-up up until 46 years of age, found that women with self-reported PCOS had 89 
greater weight gain between the ages of 14 and 31 years, while they exhibited comparable degrees of BMI90 
increase between the ages of 31 and 46 years (25). Interestingly, an Australian longitudinal population-based 91 
study assessed three BMI trajectories (low-stable, moderately-rising and high-rising) and found that 92 
compared with controls, women with PCOS were 1.6 times more likely to belong to the moderately-rising 93 
trajectory and 4.7 times more likely to belong to the high-rising trajectory (27). Taken together, these studies 94 
indicate that young women with PCOS have higher BMI and weight gain than similarly aged women without 95 
PCOS, which might expose the women with PCOS to increased risk for abnormal glucose metabolism, 96 
dyslipidemia, hypertension and cardiovascular diseases (CVD). 97 
Abnormal glucose metabolism 98 
A systematic review and meta-analysis recently concluded that women with PCOS have an increased risk of 99 
prediabetes and T2D and that the risk differed by ethnicity and BMI (28). Interestingly, among European 100 
women, the prevalence of T2D did not differ between women with and without PCOS (28), however, the 101 
effect of aging was not investigated. In general, aging and hypoestrogenism promote obesity and insuli 102 
resistance in all women, increasing the risk for disturbances in glucose metabolism later in life.  Even though 103 
women with PCOS present with impaired glucose metabolism at an earlier age than women without PCOS, it 104 
seems that beyond menopause women without PCOS “catch up” with the risk for T2D found in women with 105 
PCOS and consequently exhibit comparable rates of T2D (29). Indeed, the NFBC66 study showed that by 106 
age 46, the normal weight women with PCOS do not have an increased risk of pre-diabetes or T2D when 107 
compared to normal-weight controls (30). Overweight/obese women with PCOS, however, demonstrated 108 
higher risk of T2D compared to controls in the same BMI category (30). 109 
 Likewise, a prospective population-based cohort study (Tehran Lipid and Glucose Study) reported that 110 
among women over 40 years, the incidence of pre-diabetes and T2D was similar in PCOS (based on NIH 111 
criteria) and control women (31), whereas among women aged less than 40 years, the women with PCOS 112 
had significantly higher incidence of prediabetes and T2D than controls. Unfortunately, it was not reported 113 
whether PCOS women developing abnormal glucose metabolism after the age of 40 years experience greater 114 
weight gain or whether they are more obese than controls. Moreover, a large Danish nationwide register 115 
study reported that women with PCOS were diagnosed a  having T2D at a younger age than controls and 116 
that a higher proportion of PCOS women with T2D were < 40 years than found in controls with T2D (32). 117 
The opposite was found in a cross-sectional Nordic multicenter study of 876 women with PCOS, which 118 
reported the prevalence of T2D and prediabetes as comparable between women < 40 years and > 40 years. 119 
Women with prediabetes and T2D, however, were older compared to women with normal glucose tolerance 120 
(33). Interestingly, in the latter study, none of the normal-weight women with PCOS had T2D. Considere 121 
together, these studies suggest that while ethnicity impacts the risk of T2D, the prevalence of T2D does not 122 
increase with aging in women with PCOS. Long-term follow up studies are needed, however, with adequate 123 
sample sizes and well characterized PCOS populations (with adjustments for BMI and weight gain) to 124 
confirm these findings. 125 
Other common CVD risk factors in PCOS 126 
A recent systematic review and meta-analysis reportd increased prevalence of metabolic syndrome (MetS) 127 
in overweight or obese women with PCOS but not in lean ones (34). In the Tehran Lipid and Glucose Study, 128 
the incidence of hypertension, MetS, dyslipidemia and obesity were comparable between PCOS women aged 129 
> 40 years and similar aged controls, whereas among women < 40 years, women with PCOS had higher 130 
incidence of hypertension and MetS than control women (35). A Nordic cross-sectional multicenter case-131 
control study found that in women over 39 years of age, the prevalence of MetS was twofold higher in the 132 
hyperandrogenic-PCOS (HA-PCOS) group compared with the normoandrogenic-PCOS (NA-PCOS) or 133 
control groups (36). Moreover, the women over 39 years with the HA-PCOS had higher serum levels of low 134 
density lipoprotein (LDL) and triglycerides compared with controls, and higher serum levels of LDL 135 
compared with the NA-PCOS population (36).  136 
A longitudinal study of 38 PCOS and 296 control women recruited from an academic medical center 137 
demonstrated that triglyceride levels and HOMA-IR value increased more in the PCOS group than in the 138 
control group (37). In line with this, in a 11-year follow-up study, women with PCOS-like status (the 139 
presence of two of the following three features: history of irregular menstrual cycles, high free androgen 140 
index or high AMH-level) developed MetS almost three years than  controls (38). Moreover, the NFBC66 141 
study found that PCOS was associated with elevated blood pressure at age 31 and hypertension at age 46 142 
independently of overweight/obesity (39). 143 
Cardiovascular disease events 144 
Hyperandrogenemia, a key feature of PCOS, has been thought to be a risk factor for metabolic abnormalities 145 
and CVD both in PCOS and in non-PCOS women, althoug the existing literature is inconsistent. In women 146 
with PCOS, hyperandrogenemia is associated with abdominal obesity and insulin resistance and is thought to 147 
associate with an increased risk of T2D and MetS, and eventually an increased prevalence of CVD events. 148 
This assumption has been challenged by a recent study including both a meta-analysis of previously 149 
published prospective studies and a prospective population-based cohort study of 3,117 postmenopausal 150 
women with an average follow-up time of 11.1 years (Rotterdam study). That study reported that total 151 
testosterone or bioavailable testosterone levels did not associate with T2D, whereas low level of sex-152 
hormone binding globulin and high levels of total estradiol were associated with increased risk of T2D, 153 
implicating obesity rather than hyperandrogenism as the more critical risk factor (40).  154 
Another publication from the Rotterdam Study included a total of 2,578 women with a mean age of 70.2 155 
years and reported that there were no associations between high androgen levels and incidence of stroke, 156 
coronary heart disease or CVD (41). The investigators also made a sub-analysis on CVD risk in women with157 
PCOS, in which PCOS was defined based on a reported history of cycle irregularities and current high 158 
androgen levels. Women with PCOS (n=160) had a larger waist/hip ratio, a higher BMI, higher prevalence of 159 
T2D and dyslipidemia, but no increased risk for incident CVD was observed after adjusting for confounding 160 
factors (41). In line with these findings, a follow up of a relatively small cohort (n=25) of 161 
postmenopausal women, those with previous PCOS werenot associated with angiographic coronary artery 162 
disease nor increased 10-year mortality (18).  163 
The exact opposite results, however, have also beenfound. In the NFBC66 study, compared to controls 164 
women with PCOS had higher prevalence of acute myocardial infarction and CVD events, already by the ag165 
of 46 years (39). In line with that study, a large nationwide register study from Denmark reported higher 166 
CVD event rate in women with PCOS compared to controls (22.6 per 1000 patient years in PCOS vs. 13.2 167 
per 1000 patient years in controls) (42).  168 
Health related quality of life (HRQoL) 169 
As PCOS is associated with high morbidity, it is not surprising that women with PCOS have been shown t 170 
experience decreased quality of life, although long-term studies are scarce (2). Given that the HRQoL has 171 
been shown to decrease with ageing in women in general, the question is whether PCOS has additional 172 
effects on the long-term quality of life. During the reproductive years, anxiety and depression (43-45), 173 
hirsutism (46), infertility (47, 48) and obesity (49, 50) have all been shown to associate with decreased 174 
HRQoL in PCOS, psychological distress being the most c mmonly reported contributor. As there is a great 175 
of individual variation in symptomology, the most bothersome symptoms should be identified and treated 176 
effectively, preferably by utilizing a multidisciplnary approach (1).  177 
Given that several of the PCOS features, like menstrual irregularities and hyperandrogenism, decrease along 178 
age HRQoL may improve with age in women with PCOS. ur recent publication on age-related HRQoL in 179 
women with PCOS showed that decrease in HRQoL persist d between the ages of 31 and 46 years compared 180 
to controls after adjusting for BMI, education, marital status and self-reported infertility (51). Interestingly, 181 
clinical hyperandrogenism also associated with lower HRQoL, whereas testosterone levels or free androgen 182 
index (FAI) did not. This underlines the fact that esthetic aspects should not be underestimated in aging 183 
women with PCOS and that hirsutism warrants effectiv  treatments. The research community should assess 184 
in the future whether HRQoL remains low in women with PCOS beyond menopause. In addition, the 185 
intervention studies should also routinely include HRQoL questionnaire in addition to clinical measure in 186 
order to evaluate health outcomes more widely.  187 
CONCLUSION  188 
The long-term follow-up and high-quality studies in large PCOS population are lacking, and the oldest 189 
women with reliable PCOS diagnosis are not more than 70-75 years old. Only a few studies have 190 
investigated the age at menopause in women with PCOS, but the available evidence indicates women with 191 
PCOS have a later age at menopause than women without PCOS. Whether this translates into increased 192 
fertility for women with PCOS in their later reproductive years remains to be determined. The recent 193 
publications indicate that late reproductive aged women with PCOS have an increased risk for obesity and 194 
that overweight and obese women with PCOS, but not hose with normal BMI, seem to present risk for T2D. 195 
Later age at menopause and consequently longer estrog n exposure might protect women with PCOS from 196 
CVDs.  197 
In most studies, however, the PCOS exhibiting CVD are younger than women without PCOS and exhibiting 198 
CVD. Most of the studies have been limited with toosmall sample sizes to detect a difference between 199 
women with PCOS and non-PCOS controls. Moreover, th definitions of PCOS and the CVD events have 200 
been very variable.  201 
In conclusion, future research is needed to establih the metabolic and cardiovascular disease profiles in 202 
women with PCOS in their late reproductive years as well as beyond menopause. Although there are no 203 
long-term data on the morbidity for CVD in PCOS, it is advisable to perform a careful metabolic and 204 
cardiovascular assessment in affected women in order to prevent conditions leading to CVD. Those 205 
individuals at increased risk (obese, family history) should be identified early during childhood. This means 206 
targeted screening of girls at risk for PCOS to enable lifestyle changes and prescription of medication 207 
according to generally accepted criteria. In addition, women with PCOS should be systematically screened 208 
using HRQoL so that comprehensive improvements in their HRQoL can be achieved. 209 
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